

Table SI. Best response following third-line treatment in platinum-doublet group.

Response	CBDCA+VP-16 n=6	CBDCA+PTX n=9
Complete response	0	0
Partial response	0	4
Stable disease	4	1
Progressive disease	2	4
Response rate, %	0	55.5
Disease control rate, %	66.7	44.4

CBDCA: carboplatin, VP-16: etoposide, PTX: paclitaxel.